We discuss the mechanistic consequences of elevated extracellular adenosine in the GC microenvironment and highlight considerations for targeting Adora2b to improve outcomes in high-risk or diagnosed GC patients (32). The gene discussed is ADORA2B; the disease is gastric cancer.